Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02654964 · ClinicalTrials.gov registry record · Phase 1

Cancer Stem Cell High-Throughput Drug Screening Study

A Phase 1 study of Glioblastoma Multiforme, sponsored by Swedish Medical Center.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT02654964 is a Phase 1 study of Glioblastoma Multiforme that has completed, run by Swedish Medical Center. The registered enrollment target is 9 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02654964, a Phase 1 study of Glioblastoma Multiforme, has completed, sponsored by Swedish Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

A study to determine the safety of CSC/ HTS-based combination drug therapy in subjects who have GBM that has recurred or progressed following prior radiation therapy and TMZ.

Conditions Studied

Interventions

  • DRUG Combination Drug Therapy

Study Locations (1)

Washington

  • Swedish Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2015-12
Est. Completion 2023-06
Phase Phase 1

Sponsor

Swedish Medical Center

30 total trials

What the Registry Record Tells You About NCT02654964

The ClinicalTrials.gov registry entry for NCT02654964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (91% lower). The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Combination Drug Therapy is the first listed.

NCT02654964 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT02654964 about?

NCT02654964 is a clinical study titled "Cancer Stem Cell High-Throughput Drug Screening Study". A study to determine the safety of CSC/ HTS-based combination drug therapy in subjects who have GBM that has recurred or progressed following prior radiation therapy and TMZ.

What is the current status of trial NCT02654964?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-12. Estimated completion is 2023-06.

What conditions does trial NCT02654964 study?

This clinical trial studies the following conditions: Glioblastoma Multiforme.

What interventions are being tested in trial NCT02654964?

The interventions under investigation include: Combination Drug Therapy (DRUG).

Who is sponsoring clinical trial NCT02654964?

This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02654964 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioblastoma Multiforme

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.